Clinical Pearls

Bite-sized clinical takeaways from today's literature (sources from Dec 01 – Jun 21)

• Consider integrating genetic polymorphism data into your PBPK/PD models when optimizing clozapine dosing for treatment-resistant schizophrenia to enhance precision.
• Monitor metabolic parameters closely in patients with affective disorders prescribed cariprazine, as recent meta-analyses provide specific evidence-based safety profiles for this second-generation antipsychotic.
• When managing antipsychotic-induced weight gain, utilize network meta-analysis data to select from a broad range of pharmacological and non-pharmacological interventions rather than relying on a single strategy.
• Evaluate the potential off-label use of roflumilast for patients with schizophrenia who have prominent cognitive deficits, given pilot evidence suggesting it may enhance memory network activity.
• Reassess the mechanism of clozapine's efficacy by considering muscarinic receptor agonism alongside traditional dopaminergic blockade when treatment response is suboptimal.
• Exercise caution when prescribing psychostimulants or atomoxetine to adults with a history of psychosis, as cohort studies indicate an increased risk of psychosis recurrence.
• Apply the Rawlings–Thompson A-F classification system and low-slow titration techniques in your practice to systematically manage psychopharmacology side effects.
• Focus VR-assisted avatar therapy interventions on context-specific confrontation processes for auditory hallucinations rather than general emotional coping skills, as recent trial data suggests the latter is not the primary mechanism of benefit.
• Investigate glutamate levels and cerebral blood flow changes in patients with treatment-resistant schizophrenia during clozapine therapy to better understand neurobiological responses to treatment.